Briefs: BioSante receives milestone payment

LINCOLNSHIRE -- BioSante Pharmaceuticals Inc. announced receipt of a $3.5 million milestone payment under the terms of its Elestrin licensing agreement with Bradley Pharmaceuticals Inc. The payment is the second of two triggered by the December 2006 U.S. Food and Drug Administration approval of Elestrin, an estradiol gel, and brings the total payments received to $14 million. BioSante has the right under the agreement to receive up to an additional $40 million upon the achievement of certain sales-based milestones and has been receiving royalties since the mid-year launch of the product.

Company's test used in Alzheimer's study

VERNON HILLS -- Applied NeuroSolutions Inc., a company focused on the development of an integrated portfolio of products for the treatment and diagnosis of Alzheimer's disease, reported that a peer-reviewed paper on a CSF-phosphorylated tau "biomarker" is highlighted in the Dec. 11 issue of the print edition of Neurology. In an international, multicenter study led by Dr. Harald Hampel, the biomarker test has shown to be a predictor in the transition from mild cognitive impairment to Alzheimer's disease in a relatively short and clinically relevant observation interval.